Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
2.66
Nov 20 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Aftermarket Close
2.65
Aftermarket • 7:30 PM ET Dollar change-0.01 Percentage change(-0.32%)
Index
-
Market Cap
28.91M
Enterprise Value
20.96M
Income
-20.10M
Sales
58.52M
Book/sh
2.90
Cash/sh
2.35
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
76
IPO
Sep 24, 2008
P/E
-
Forward P/E
13.53
PEG
-
P/S
0.49
P/B
0.92
P/C
1.13
P/FCF
8.03
EV/EBITDA
-
EV/Sales
0.36
Quick Ratio
0.96
Current Ratio
1.07
Debt/Eq
0.56
LT Debt/Eq
0.30
Option/Short
No / Yes
EPS (ttm)
-1.79
EPS next Y
0.20
EPS next Q
-0.15
EPS this Y
63.22%
EPS next Y
146.09%
EPS next 5Y
-
EPS past 3/5Y
39.03% 55.93%
Sales past 3/5Y
-18.77% -2.59%
EPS Y/Y TTM
7.24%
Sales Y/Y TTM
-8.12%
EPS Q/Q
-159.77%
Sales Q/Q
6.87%
Insider Own
8.26%
Insider Trans
0.00%
Inst Own
34.18%
Inst Trans
-4.26%
ROA
-17.93%
ROE
-73.44%
ROIC
-49.02%
Gross Margin
58.54%
Oper. Margin
-16.51%
Profit Margin
-34.34%
SMA20
31.10%
SMA50
29.71%
SMA200
16.91%
Trades
Shs Outstand
10.87M
Shs Float
9.97M
52W High
3.07 -13.21%
52W Low
1.75 52.00%
Volatility
2.86% 4.87%
ATR (14)
0.13
RSI (14)
79.51
Beta
-0.00
Rel Volume
1.07
Avg Volume
138.21K
Volume
148,519
Perf Week
49.44%
Perf Month
34.34%
Perf Quarter
15.15%
Perf Half Y
21.46%
Perf YTD
2.31%
Perf Year
37.11%
Perf 3Y
10.83%
Perf 5Y
-93.42%
Perf 10Y
-100.00%
Prev Close
2.66
Price
2.66
Change %
0.00%
Consensus
Buy
Avg. Price Target
$8.85
Implied Upside
+232.7%
Analysts5incl. previous ratings
Rating Distribution3 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 17, 2026Downgrade
MMaxim Group
Buy → Hold
Nov 17, 2026Downgrade
LLake Street
Buy → Hold$2.70+1.5%
Jul 01, 2025Initiated
LLake Street
Buy$8+200.8%
Jun 30, 2025Initiated
AAscendiant Capital Markets
Buy$12+351.1%
Mar 30, 2021Initiated
CCantor Fitzgerald
Overweight$11+313.5%
May 29, 2020Initiated
HH.C. Wainwright
Buy$3+12.8%
Aytu BioPharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. Its products include EXXUA, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, and Metadate CD. The company was founded on August 9, 2002 and is headquartered in Denver, CO.
CEO & DirectorMr. Joshua R. Disbrow
CFOMr. Ryan J. Selhorn CPA
Chief Business OfficerMr. Jarrett T. Disbrow Ph.D.
Chief Commercial OfficerMr. Greg Pyszczymuka
Vice President of OperationsMs. Margaret Cabano